Summary
University College London (UCL), a subsidiary of University of London is an educational institute that provides undergraduate, post-graduate, and life learning programs. The institute offers programs in the areas of arts and humanities, Bartlett faculty of the built environment, brain sciences, engineering, laws, life sciences, mathematical and physical sciences, medical sciences, population health sciences and social, and historical sciences. Its services include alumini services, infrastructure management, finance and business affairs, human resource development, information services, library services, public and cultural engagement, and student and registry services. The institute conducts research in partnership with other research organisations, commerce and industry, and healthcare providers. UCL is headquartered in London, the UK.
University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University College London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
University College London, Medical Devices Deals, 2011 to YTD 2017 11
University College London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
University College London, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 16
Puridify Raises USD3.4 Million in Series A Financing 17
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 18
Puridify Raises USD1.43 Million in Seed Funding 19
Canbex Therapeutics Raises US$3 Million In Venture Financing 20
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 21
Partnerships 22
Sygnature Discovery and UCL School of Pharmacy Enter into Research Partnership 22
Cell Medica Enters into Partnership with University College London 23
Santen Pharma to Enter into Agreement with University College London 24
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 25
Teva Pharma Partners with University College London and Imanova 26
Elsevier Partners with University College London 27
University College London Enters into Research Agreement with Takeda Pharma 28
Magnus Life Science Partners with University College London 29
UCL Business Forms Joint Venture with Syncona 30
Chiesi Farmaceutici and University College London Enter into Agreement 31
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 32
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 33
Takeda Enters into R&D Agreement with University College London 34
iQur Enters into Co-Development Agreement with Six Consortium 35
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 36
Cellectis Enters Into Co-Development Agreement With University College London 37
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 38
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 39
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 40
TAP Biosystems Enters Into Co-Development Agreement With University College London 41
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 42
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 44
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 45
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 46
Eisai Enters Into Research Agreement With University College London 47
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 48
Licensing Agreements 50
TC BioPharm Enters into Licensing Agreement with University College London 50
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 51
BioKier Enters into Licensing Agreement with UCL Business 52
Achilles Therapeutics Enters into Licensing Agreement with University College London and Francis Crick Institute 53
Autolus Enters into Licensing Agreement with UCL Business 54
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 55
Oxford Pharmascience Extends Licensing Agreement With UCL Business 56
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 57
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 59
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 60
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 61
Equity Offering 62
Autolus Spin Out from University College London 62
Nanomerics Spin Out from University College London 63
Asset Transactions 64
Freeline Therapeutics Acquires Intellectual Property Rights from UCL 64
University College London - Key Competitors 65
University College London - Key Employees 66
University College London - Locations And Subsidiaries 67
Head Office 67
Other Locations & Subsidiaries 67
Joint Venture 68
Recent Developments 70
Strategy And Business Planning 70
May 03, 2016: UCLB And F-Prime Launch Orchard Therapeutics To Treat Rare Childhood Diseases 70
Government and Public Interest 71
Sep 05, 2017: Acceptance and Commitment Therapy for people with motor neuron disease 71
Aug 18, 2017: GBP5 million for new NIHR Obesity Policy Research Unit 72
Aug 17, 2017: MRC researchers win prestigious awards for contribution to neurodegeneration research 73
Apr 04, 2017: Common antibiotic may help to prevent or treat PTSD 74
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 75
Nov 30, 2016: HIV patients showing signs of multidrug resistance in Africa 76
May 24, 2016: Research points to possible new prevention strategies for ovarian cancer 77
Mar 30, 2016: Cancer drug could treat blood vessel deformities 78
Feb 16, 2016: Gene could help identify psychosis risk in cannabis users 79
Feb 15, 2016: Virtual reality therapy could help people with depression 80
Feb 11, 2016: Blocking stress protein relieves chronic pain in mice 81
Jan 29, 2016: New biomarker to assess stem cells developed 82
Jan 25, 2016: Epilepsy drug could protect nerves from damage in MS 83
Jan 18, 2016: New Alzheimer’s disease drug trial opens more sites across the South West 84
Jan 14, 2016: University College London Receives National MS Society Funding to Identify and Refine Nerve-Protecting Therapies 85
Jan 11, 2016: ReNeuron wins major UK grant to advance its exosome nanomedicine platform 86
Product News 87
Oct 12, 2017: New drug hope for patients with rare bone cancer 87
May 09, 2017: Trial to investigate if statins could become multiple sclerosis treatment 88
Feb 01, 2017: Researchers develop best-yet cell culture system for age-related macular degeneration 89
Jan 26, 2016: Epilepsy Pill May Protect Against MS-Related Nerve Damage: Phase 2 Trial Results Published 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91
List of Tables
University College London, Pharmaceuticals & Healthcare, Key Facts 2
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University College London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University College London, Deals By Therapy Area, 2011 to YTD 2017 10
University College London, Medical Devices Deals, 2011 to YTD 2017 11
University College London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 16
Puridify Raises USD3.4 Million in Series A Financing 17
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 18
Puridify Raises USD1.43 Million in Seed Funding 19
Canbex Therapeutics Raises US$3 Million In Venture Financing 20
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 21
Sygnature Discovery and UCL School of Pharmacy Enter into Research Partnership 22
Cell Medica Enters into Partnership with University College London 23
Santen Pharma to Enter into Agreement with University College London 24
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 25
Teva Pharma Partners with University College London and Imanova 26
Elsevier Partners with University College London 27
University College London Enters into Research Agreement with Takeda Pharma 28
Magnus Life Science Partners with University College London 29
UCL Business Forms Joint Venture with Syncona 30
Chiesi Farmaceutici and University College London Enter into Agreement 31
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 32
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 33
Takeda Enters into R&D Agreement with University College London 34
iQur Enters into Co-Development Agreement with Six Consortium 35
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 36
Cellectis Enters Into Co-Development Agreement With University College London 37
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 38
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 39
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 40
TAP Biosystems Enters Into Co-Development Agreement With University College London 41
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 42
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 44
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 45
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 46
Eisai Enters Into Research Agreement With University College London 47
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 48
TC BioPharm Enters into Licensing Agreement with University College London 50
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 51
BioKier Enters into Licensing Agreement with UCL Business 52
Achilles Therapeutics Enters into Licensing Agreement with University College London and Francis Crick Institute 53
Autolus Enters into Licensing Agreement with UCL Business 54
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 55
Oxford Pharmascience Extends Licensing Agreement With UCL Business 56
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 57
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 59
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 60
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 61
Autolus Spin Out from University College London 62
Nanomerics Spin Out from University College London 63
Freeline Therapeutics Acquires Intellectual Property Rights from UCL 64
University College London, Key Competitors 65
University College London, Key Employees 66
University College London, Subsidiaries 67
University College London, Joint Venture 68
